Financial Ratios Seelos Therapeutics, Inc.
Stocks
SEELQ
US81577F4063
Biotechnology & Medical Research
|
Market Closed -
OTC Markets
12:25:32 2026-06-01 EDT
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | +9,900.00% |
|
-.--% | +9,900.00% |
| 12-28 | Motion for Asset Sale Approved for Seelos Therapeutics, Inc. | CI |
| 25-10-21 | GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q). | CI |
| Fiscal Period: December | 2016 (USD) | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -307.29 | -82.02 | -76.33 | -83.43 | -179.75 | |||
Return on Total Capital | 1.53K | -190.81 | -87.03 | -103.33 | 518.1 | |||
Return On Equity % | 2.18K | -1.49K | -220.55 | -314.84 | 171.72 | |||
Return on Common Equity | 2.18K | -1.49K | -220.55 | -314.84 | 171.72 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 100 | - | - | - | -1.27K | |||
SG&A Margin | 1.48K | - | - | - | 571.27 | |||
EBITDA Margin % | -7.39K | - | - | - | - | |||
EBITA Margin % | -7.4K | - | - | - | -1.84K | |||
EBIT Margin % | -7.4K | - | - | - | -1.84K | |||
Income From Continuing Operations Margin % | -13.67K | - | - | - | -1.72K | |||
Net Income Margin % | -13.67K | - | - | - | -1.72K | |||
Net Avail. For Common Margin % | -13.67K | - | - | - | -1.72K | |||
Normalized Net Income Margin | -8.19K | - | - | - | -756.98 | |||
Levered Free Cash Flow Margin | -2.47K | - | - | - | -232.17 | |||
Unlevered Free Cash Flow Margin | -2.47K | - | - | - | -230.04 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.07 | - | - | - | 0.16 | |||
Fixed Assets Turnover | - | - | - | - | 50.64 | |||
Short Term Liquidity | ||||||||
Current Ratio | 1.03 | 2.35 | 10.07 | 0.9 | 0.14 | |||
Quick Ratio | 0.95 | 2.11 | 9.5 | 0.62 | 0.1 | |||
Operating Cash Flow to Current Liabilities | -1.79 | -2.82 | -5.91 | -2.45 | -0.61 | |||
Average Days Payable Outstanding | - | 44.7 | - | - | 121.37 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | - | 378.07 | 33.07 | -189.63 | -42.46 | |||
Total Debt / Total Capital | - | 79.08 | 24.85 | 211.57 | -73.79 | |||
LT Debt/Equity | - | 283.55 | 31.21 | -77.27 | - | |||
Long-Term Debt / Total Capital | - | 59.31 | 23.45 | 86.21 | - | |||
Total Liabilities / Total Assets | 100.06 | 85.3 | 31.35 | 146.65 | 718.49 | |||
EBIT / Interest Expense | -956.79 | -114.38 | -38.59 | -5.07K | -539.99 | |||
EBITDA / Interest Expense | -955.38 | - | -38.53 | -5.06K | -538.65 | |||
(EBITDA - Capex) / Interest Expense | -955.38 | - | -38.53 | -5.06K | -538.65 | |||
Total Debt / EBITDA | - | - | -0.31 | -0.28 | -0.35 | |||
Net Debt / EBITDA | 0.37 | - | 0.97 | -0.06 | -0.28 | |||
Total Debt / (EBITDA - Capex) | - | - | -0.31 | -0.28 | -0.35 | |||
Net Debt / (EBITDA - Capex) | 0.37 | - | 0.97 | -0.06 | -0.28 | |||
Growth Over Prior Year | ||||||||
Gross Profit, 1 Yr. Growth % | - | -50.5 | - | - | -52.38 | |||
EBITDA, 1 Yr. Growth % | 781.51 | - | - | - | - | |||
EBITA, 1 Yr. Growth % | 771.45 | -32.39 | 228.74 | 14.99 | -42.89 | |||
EBIT, 1 Yr. Growth % | 771.45 | -32.39 | 228.74 | 14.99 | -42.89 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 1.37K | -62.73 | 245.78 | 11.33 | -48.48 | |||
Net Income, 1 Yr. Growth % | 1.37K | -62.73 | 245.78 | 11.33 | -48.48 | |||
Normalized Net Income, 1 Yr. Growth % | 1.38K | -61.13 | 235.27 | 10.11 | -62.16 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | 70.31 | -4.84 | -62.73 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | - | 84.62 | -79.17 | |||
Total Assets, 1 Yr. Growth % | 5.71K | 57.66 | 377.31 | -72.76 | -76.18 | |||
Tangible Book Value, 1 Yr. Growth % | -99.85 | -36.84K | 2.13K | -118.51 | 215.8 | |||
Common Equity, 1 Yr. Growth % | -99.85 | -36.84K | 2.13K | -118.51 | 215.8 | |||
Cash From Operations, 1 Yr. Growth % | 1.12K | 8.33 | 134.28 | 25.74 | -61.18 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 778.21 | 75.8 | 85.97 | 17.55 | -85.63 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 850.24 | 76.66 | 89 | 15.3 | -85.76 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
EBITDA, 2 Yr. CAGR % | 62.01 | - | - | - | - | |||
EBITA, 2 Yr. CAGR % | 61.24 | 142.73 | 49.08 | 94.43 | -18.96 | |||
EBIT, 2 Yr. CAGR % | 61.24 | 142.73 | 49.08 | 94.43 | -18.96 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 108.87 | 134.45 | 13.52 | 96.21 | -24.27 | |||
Net Income, 2 Yr. CAGR % | 1.16K | 134.45 | 13.52 | 96.21 | -24.27 | |||
Normalized Net Income, 2 Yr. CAGR % | 108.32 | 140.04 | 14.15 | 92.14 | -35.45 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | - | 27.3 | -40.45 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | - | - | -37.98 | |||
Total Assets, 2 Yr. CAGR % | 28.63 | 857.04 | 174.32 | 14.03 | -74.53 | |||
Tangible Book Value, 2 Yr. CAGR % | -96 | -26.07 | 8.95K | 103.12 | -23.54 | |||
Common Equity, 2 Yr. CAGR % | -96 | -26.07 | 8.95K | 103.12 | -23.54 | |||
Cash From Operations, 2 Yr. CAGR % | 35.81 | 263.7 | 59.31 | 71.63 | -30.14 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 292.92 | 80.81 | 47.86 | -58.91 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 309.71 | 82.72 | 47.62 | -59.48 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
EBITA, 3 Yr. CAGR % | 298.9 | 20.68 | 168.55 | 36.72 | 29.24 | |||
EBIT, 3 Yr. CAGR % | 298.9 | 20.68 | 168.55 | 36.72 | 29.24 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 389.45 | 17.58 | 166.87 | 12.78 | 25.64 | |||
Net Income, 3 Yr. CAGR % | 389.45 | 290.41 | 166.87 | 12.78 | 25.64 | |||
Normalized Net Income, 3 Yr. CAGR % | 382.64 | 19.03 | 168.32 | 12.79 | 11.79 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | - | -15.47 | |||
Total Assets, 3 Yr. CAGR % | - | 37.66 | 658.96 | 27.03 | -32.34 | |||
Tangible Book Value, 3 Yr. CAGR % | -69.79 | -16.2 | 130.09 | 1.05K | 135.31 | |||
Common Equity, 3 Yr. CAGR % | -69.79 | -16.2 | 130.09 | 1.05K | 135.31 | |||
Cash From Operations, 3 Yr. CAGR % | - | 25.95 | 214.1 | 47.22 | 4.57 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 206.21 | 56.64 | -32.03 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 216.57 | 56.73 | -32.3 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
EBITA, 5 Yr. CAGR % | - | - | 169.08 | 46.05 | 66.3 | |||
EBIT, 5 Yr. CAGR % | - | - | 169.08 | 46.05 | 66.3 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 172.8 | 44.31 | 61.25 | |||
Net Income, 5 Yr. CAGR % | - | - | 172.8 | 196.48 | 61.25 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 171.12 | 44.16 | 51.76 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | -1.84 | - | |||
Total Assets, 5 Yr. CAGR % | - | - | - | 27.67 | 95.24 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | 195.6 | 19.41 | 48.08 | |||
Common Equity, 5 Yr. CAGR % | - | - | 195.6 | 19.41 | 48.08 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | - | 42.55 | 72.16 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 37.13 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 39.1 |
- Stock Market
- Stocks
- SEELQ Stock
- Financials Seelos Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















